{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:43:14Z","timestamp":1794606194640,"version":"4.9.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11926-021-01011-z","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T07:20:11Z","timestamp":1621495211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Advances in the Treatment of Behcet\u2019s Disease"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6653-1758","authenticated-orcid":false,"given":"Fatma","family":"Alibaz-Oner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-5806","authenticated-orcid":false,"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"issue":"1","key":"1011_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60\u201376.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"1011_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","volume":"11","author":"D McGonagle","year":"2015","unstructured":"McGonagle D, Aydin SZ, G\u00fcl A, Mahr A, Direskeneli H. \u2018MHC-I-opathy\u2019-unified concept for spondyloarthritis and Beh\u00e7et disease. Nat Rev Rheumatol. 2015;11(12):731\u201340.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1011_CR3","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.semarthrit.2020.08.010","volume":"50","author":"A G\u00f3mez-G\u00f3mez","year":"2020","unstructured":"G\u00f3mez-G\u00f3mez A, Loza E, Rosario MP, Espinosa G, de Morales J, Herrera JM, et al. Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: a systematic literature review. Semin Arthritis Rheum. 2020;50(6):1299\u2013306.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1011_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12886-018-0929-5","volume":"18","author":"H Celiker","year":"2018","unstructured":"Celiker H, Kazokoglu H, Direskeneli H. Conventional immunosuppressive therapy in severe Behcet\u2019s uveitis: the switch rate to the biological agents. BMC Ophthalmol. 2018;18(1):261.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1011_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","volume":"45","author":"C Mat","year":"2006","unstructured":"Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, et al. A double-blind trial of depot corticosteroids in Beh\u00e7et\u2019s syndrome. Rheumatology (Oxford). 2006;45(3):348\u201352.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1011_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/1756-185X.13095","volume":"20","author":"M Mohammadi","year":"2017","unstructured":"Mohammadi M, Shahram F, Shams H, Akhlaghi M, Ashofteh F, Davatchi F. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet\u2019s disease: a pilot double-blind controlled study. Int J Rheum Dis. 2017;20(9):1269\u201376.","journal-title":"Int J Rheum Dis"},{"key":"1011_CR7","doi-asserted-by":"crossref","unstructured":"Piga M, Floris A, Espinosa G, Serpa Pinto L, Kougkas N, Lo Monaco A, et al. Development and preliminary validation of the Beh\u00e7et\u2019s syndrome Overall Damage Index (BODI). RMD Open. 2020;6(2).","DOI":"10.1136\/rmdopen-2020-001192"},{"issue":"4","key":"1011_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/art.1780400425","volume":"40","author":"V Hamuryudan","year":"1997","unstructured":"Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, T\u00fcz\u00fcn Y, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769\u201374.","journal-title":"Arthritis Rheum"},{"key":"1011_CR9","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Ad\u00e1n A, et al. Long term follow-up and optimization of infliximab in refractory uveitis due to Beh\u00e7et's disease. National study of 103 Caucasian patients. J Rheumatol. 2020.","DOI":"10.1136\/annrheumdis-2020-eular.1607"},{"issue":"3","key":"1011_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis. Arch Ophthalmol. 2011;129(3):288\u201394.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"1011_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5152\/eurjrheum.2017.16112","volume":"4","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, Cassar\u00e0 E, Kaloudi O. Rapid loss of efficacy of biosimilar infliximab in three patients with Beh\u00e7et\u2019s disease after switching from infliximab originator. Eur J Rheumatol. 2017;4(4):288\u201390.","journal-title":"Eur J Rheumatol"},{"issue":"5","key":"1011_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11739-018-1970-3","volume":"14","author":"G Lopalco","year":"2019","unstructured":"Lopalco G, Venerito V, Cantarini L, Emmi G, Prisco D, Iannone F. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Beh\u00e7et\u2019s disease. Intern Emerg Med. 2019;14(5):719\u201322.","journal-title":"Intern Emerg Med"},{"issue":"6","key":"1011_CR13","first-page":"111","volume":"37 Suppl 121","author":"E Dincses","year":"2019","unstructured":"Dincses E, Esatoglu SN, Ozguler Y, Uygunoglu U, Hamuryudan V, Seyahi E, et al. Biosimilar infliximab for Beh\u00e7et\u2019s syndrome: a case series. Clin Exp Rheumatol. 2019;37 Suppl 121(6):111\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"1011_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3389\/fmed.2020.00418","volume":"7","author":"L Xue","year":"2020","unstructured":"Xue L, van Bilsen K, Schreurs MWJ, van Velthoven MEJ, Missotten TO, Thiadens A, et al. Are patients at risk for recurrent disease activity after switching from Remicade(\u00ae) to Remsima(\u00ae)? An observational study. Front Med (Lausanne). 2020;7:418.","journal-title":"Front Med (Lausanne)"},{"key":"1011_CR15","doi-asserted-by":"crossref","unstructured":"Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020.","DOI":"10.1136\/annrheumdis-2020-218946"},{"issue":"6","key":"1011_CR16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318 The most important current Recommendation for the Management of BD.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1011_CR17","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10067-014-2585-3","volume":"33","author":"F Alibaz-Oner","year":"2014","unstructured":"Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, et al. Unmet need in Behcet\u2019s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33(12):1773\u20136.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1011_CR18","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98\u2013105.","journal-title":"J Rheumatol"},{"issue":"1","key":"1011_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61\u201370.","journal-title":"Semin Arthritis Rheum"},{"issue":"16","key":"1011_CR20","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Beh\u00e7et\u2019s syndrome--a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138.","journal-title":"N Engl J Med"},{"issue":"20","key":"1011_CR21","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome. N Engl J Med. 2019;381(20):1918\u201328 An important Phase-3 study demonstrating the efficacy and safety of Apremilast for oral ulcer treatment in BD patients.","journal-title":"N Engl J Med"},{"issue":"12","key":"1011_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2019-215437","volume":"78","author":"G Lopalco","year":"2019","unstructured":"Lopalco G, Venerito V, Leccese P, Emmi G, Cantarini L, Lascaro N, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Beh\u00e7et's disease. Ann Rheum Dis. 2019;78(12):1736\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1011_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/rheumatology\/kez267","volume":"59","author":"G De Luca","year":"2020","unstructured":"De Luca G, Cariddi A, Campochiaro C, Vanni D, Boffini N, Tomelleri A, et al. Efficacy and safety of apremilast for Beh\u00e7et\u2019s syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020;59(1):171\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"1011_CR24","doi-asserted-by":"crossref","unstructured":"Hirahara L, Kirino Y, Soejima Y, Takeno M, Takase-Minegishi K, Yoshimi R, et al. Efficacy and safety of apremilast for 3 months in Beh\u00e7et\u2019s disease: a prospective observational study. Mod Rheumatol. 2020:1\u20136.","DOI":"10.1080\/14397595.2020.1830504"},{"issue":"3","key":"1011_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et's disease: a case series. Dermatology. 2014;228(3):211\u20134.","journal-title":"Dermatology."},{"issue":"7","key":"1011_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol. 2015;34(7):1293\u2013301.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1011_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","volume":"19","author":"PC Grayson","year":"2017","unstructured":"Grayson PC, Yazici Y, Merideth M, Sen HN, Davis M, Novakovich E, et al. Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: a pilot open-label study. Arthritis Res Ther. 2017;19(1):69.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1011_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","volume":"28","author":"C Fabiani","year":"2020","unstructured":"Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Di Scala G, et al. The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm. 2020;28(2):298\u2013304 Study suggesting a beneficial role of anti-IL-1 treatment in BD with uveitis.","journal-title":"Ocul Immunol Inflamm"},{"key":"1011_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","volume":"82","author":"A Mirouse","year":"2017","unstructured":"Mirouse A, Barete S, Monfort JB, Resche-Rigon M, Bouyer AS, Comarmond C, et al. Ustekinumab for Beh\u00e7et\u2019s disease. J Autoimmun. 2017;82:41\u20136.","journal-title":"J Autoimmun"},{"issue":"10","key":"1011_CR30","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/art.40912","volume":"71","author":"A Mirouse","year":"2019","unstructured":"Mirouse A, Barete S, Desbois AC, Comarmond C, S\u00e8ne D, Domont F, et al. Long-term outcome of ustekinumab therapy for Beh\u00e7et\u2019s disease. Arthritis Rheum. 2019;71(10):1727\u201332 Study suggesting a beneficial role of Ustekinumab in BD.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1011_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11739-019-02035-1","volume":"14","author":"SN Esatoglu","year":"2019","unstructured":"Esatoglu SN, Hatemi G. Update on the treatment of Beh\u00e7et\u2019s syndrome. Intern Emerg Med. 2019;14(5):661\u201375.","journal-title":"Intern Emerg Med"},{"issue":"4","key":"1011_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","volume":"50","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet\u2019s disease: a systematic literature review. Semin Arthritis Rheum. 2020;50(4):797\u2013804 A meta-analysis summarizing data on Tocilizumab use in BD.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"1011_CR33","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","volume":"79","author":"F Fagni","year":"2020","unstructured":"Fagni F, Bettiol A, Talarico R, Lopalco G, Silvestri E, Urban ML, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et\u2019s phenotype: a multicentre study. Ann Rheum Dis. 2020;79(8):1098\u2013104 Study suggesting a beneficial role of Secukinumab in BD.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1011_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, T\u00fcz\u00fcn Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med. 1990;322(5):281\u20135.","journal-title":"N Engl J Med"},{"issue":"3 Suppl 4","key":"1011_CR35","first-page":"136","volume":"20","author":"D BenEzra","year":"1988","unstructured":"BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome. Transplant Proc. 1988;20(3 Suppl 4):136\u201343.","journal-title":"Transplant Proc"},{"issue":"4","key":"1011_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, T\u00fcz\u00fcn B, I\u015f\u00e7imen A, T\u00fcz\u00fcn Y, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial. Br J Ophthalmol. 1992;76(4):241\u20133.","journal-title":"Br J Ophthalmol"},{"issue":"8647","key":"1011_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet. 1989;1(8647):1093\u20136.","journal-title":"Lancet."},{"issue":"3","key":"1011_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/09273948.2019.1587473","volume":"28","author":"H Eser-Ozturk","year":"2020","unstructured":"Eser-Ozturk H, Sullu Y. The results of interferon-alpha treatment in Beh\u00e7et uveitis. Ocul Immunol Inflamm. 2020;28(3):498\u2013504.","journal-title":"Ocul Immunol Inflamm"},{"key":"1011_CR39","doi-asserted-by":"publisher","first-page":"204062231984788","DOI":"10.1177\/2040622319847881","volume":"10","author":"J Shi","year":"2019","unstructured":"Shi J, Zhao C, Zhou J, Liu J, Wang L, Gao F, et al. Effectiveness and safety of interferon \u03b12a as an add-on treatment for refractory Beh\u00e7et\u2019s uveitis. Ther Adv Chronic Dis. 2019;10:2040622319847881.","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"1011_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1167\/iovs.18-25548","volume":"60","author":"O Albayrak","year":"2019","unstructured":"Albayrak O, Oray M, Can F, Uludag Kirimli G, Gul A, Tugal-Tutkun I, et al. Effect of interferon alfa-2a treatment on adaptive and innate immune systems in patients with Beh\u00e7et disease uveitis. Invest Ophthalmol Vis Sci. 2019;60(1):52\u201363 Study investigating the mechanism-of-action of IFN\u03b1 in BD.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1011_CR41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320\u201335.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1011_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","volume":"25","author":"E Diwo","year":"2017","unstructured":"Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Beh\u00e7et disease. Ocul Immunol Inflamm. 2017;25(1):76\u201384.","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"1011_CR43","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CM Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, M\u00f6hle A, Vonthein R, St\u00f6biger N, K\u00f6tter I. Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum. 2010;62(9):2796\u2013805.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"1011_CR44","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/annrheumdis-2016-eular.2780","volume":"75","author":"I K\u00f6tter","year":"2016","unstructured":"K\u00f6tter I, Vonthein R, Schoenfisch B, Xenitidis T, Doycheva D, Henes J, et al. AB0545 Interferon Alpha2a versus cyclosporin A for the treatment of severe ocular Behcet\u2019s disease \u2013 a prospective, randomised, single blind, national multicenter trial (INCYTOB). Ann Rheum Dis. 2016;75(Suppl 2):1091.","journal-title":"Ann Rheum Dis"},{"key":"1011_CR45","doi-asserted-by":"crossref","unstructured":"De Simone L, Invernizzi A, Aldigeri R, Mastrofilippo V, Marvisi C, Gozzi F, et al. Effectiveness of infliximab and interferon alpha-2a for the treatment of Beh\u00e7et\u2019s uveitis: customizing therapy according to the Clinical Features. Ocul Immunol Inflamm. 2020:1-9.","DOI":"10.1080\/09273948.2020.1815797"},{"issue":"2","key":"1011_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","volume":"28","author":"N Yal\u00e7indag","year":"2020","unstructured":"Yal\u00e7indag N, K\u00f6se HC. Comparison of the treatment results for Beh\u00e7et uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm. 2020;28(2):305\u201314.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"1011_CR47","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","volume":"74","author":"S Lightman","year":"2015","unstructured":"Lightman S, Taylor SR, Bunce C, Longhurst H, Lynn W, Moots R, et al. Pegylated interferon-\u03b1-2b reduces corticosteroid requirement in patients with Beh\u00e7et\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1011_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/09273948.2017.1332768","volume":"27","author":"H Celiker","year":"2019","unstructured":"Celiker H, Kazokoglu H, Direskeneli H. Long-term efficacy of pegylated interferon alpha-2b in Beh\u00e7et\u2019s uveitis: a small case series. Ocul Immunol Inflamm. 2019;27(1):15\u201322.","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"1011_CR49","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478\u201384.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1011_CR50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med. 2004;140(5):404\u20136.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1011_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, et al. Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183\u20139.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"1011_CR52","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A, et al. Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"10050","key":"1011_CR53","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183\u201392.","journal-title":"Lancet."},{"key":"1011_CR54","doi-asserted-by":"crossref","unstructured":"Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, et al. Anti-TNF-\u03b1 therapy for refractory uveitis associated with Beh\u00e7et\u2019s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2020:1-8.","DOI":"10.1080\/09273948.2020.1791346"},{"issue":"6","key":"1011_CR55","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","volume":"68","author":"H Vallet","year":"2016","unstructured":"Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheum. 2016;68(6):1522\u201330.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1011_CR56","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"\u2022 Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Demetrio-Pablo R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: national multicenter study of 177 cases. Arthritis Rheum. 2019;71(12):2081\u20139 A comparative study of infliximab vs adalimumab in BD uveitis.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1011_CR57","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","volume":"121","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et\u2019s disease: a multicenter study. Ophthalmology. 2014;121(10):1877\u201384.","journal-title":"Ophthalmology."},{"key":"1011_CR58","doi-asserted-by":"crossref","unstructured":"K\u00f6se HC, Yal\u00e7\u0131nda\u011f N. Clinical follow-up of patients with Beh\u00e7et uveitis after discontinuation of infliximab therapy. Ocul Immunol Inflamm. 2020:1-5.","DOI":"10.1080\/09273948.2020.1774907"},{"issue":"1","key":"1011_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/09273948.2016.1239746","volume":"25","author":"H Keino","year":"2017","unstructured":"Keino H, Okada AA, Watanabe T, Nakayama M, Nakamura T. Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Beh\u00e7et disease: a 2-year follow-up study. Ocul Immunol Inflamm. 2017;25(1):46\u201351.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"1011_CR60","first-page":"86","volume":"35 Suppl 108","author":"G Guzelant","year":"2017","unstructured":"Guzelant G, Ucar D, Esatoglu SN, Hatemi G, Ozyazgan Y, Yurdakul S, et al. Infliximab for uveitis of Beh\u00e7et's syndrome: a trend for earlier initiation. Clin Exp Rheumatol. 2017;35 Suppl 108(6):86\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1011_CR61","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191\u20137.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1011_CR62","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","volume":"37","author":"J Sota","year":"2018","unstructured":"Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37(8):2233\u201340.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1011_CR63","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281\u20136.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1011_CR64","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1011_CR65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","volume":"25","author":"IM Tugal-Tutkun","year":"2017","unstructured":"Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, Lee SCMP, Ozdal P, \u00d6zyazgan Y, et al. Safety and efficacy of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017;25(1):62\u201370.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"1011_CR66","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","volume":"26","author":"I Tugal-Tutkun","year":"2018","unstructured":"Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, G\u00fcl A. Use of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023\u201333.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"1011_CR67","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","volume":"57","author":"B Atienza-Mateo","year":"2018","unstructured":"Atienza-Mateo B, Calvo-R\u00edo V, Beltr\u00e1n E, Mart\u00ednez-Costa L, Valls-Pascual E, Hern\u00e1ndez-Garfella M, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1011_CR68","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","volume":"26","author":"H Eser Ozturk","year":"2018","unstructured":"Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the treatment of Beh\u00e7et uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2018;26(7):1005\u201314.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"1011_CR69","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246\u201352.","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"1011_CR70","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3899\/jrheum.141344","volume":"42","author":"AJ Mohammad","year":"2015","unstructured":"Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR. Alemtuzumab as remission induction therapy in Beh\u00e7et disease: a 20-year experience. J Rheumatol. 2015;42(10):1906\u201313.","journal-title":"J Rheumatol"},{"key":"1011_CR71","doi-asserted-by":"crossref","unstructured":"\u2022 Alibaz-Oner F, Ergelen R, Yildiz Y, Aldag M, Yazici A, Cefle A, et al. Femoral vein wall thickness measurement: a new diagnostic tool for Behcet\u2019s disease. Rheumatology (Oxford). 2020. Study demonstrating a high sensitivity and specificity of Doppler US to measure venous-wall thickness in BD.","DOI":"10.1093\/rheumatology\/keaa264"},{"issue":"11","key":"1011_CR72","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","volume":"53","author":"K Tascilar","year":"2014","unstructured":"Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Beh\u00e7et\u2019s syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014;53(11):2018\u201322.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1011_CR73","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2012;64(8):2753\u201360.","journal-title":"Arthritis Rheum"},{"key":"1011_CR74","doi-asserted-by":"crossref","unstructured":"\u2022 Ozguler Y, Hatemi G, Cetinkaya F, Tascilar K, Hamuryudan V, Ugurlu S, et al. Clinical course of acute deep vein thrombosis of the legs in Beh\u00e7et\u2019s syndrome, Rheumatology (Oxford). 2020;59(4):799\u2013806 Study demonstrating the beneficial role of IFN\u03b1 in vascular BD.","DOI":"10.1093\/rheumatology\/kez352"},{"issue":"9","key":"1011_CR75","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/art.40531","volume":"70","author":"G Emmi","year":"2018","unstructured":"Emmi G, Vitale A, Silvestri E, Boddi M, Becatti M, Fiorillo C, et al. Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s syndrome: a retrospective study of seventy patients with vascular involvement. Arthritis Rheum. 2018;70(9):1500\u20137.","journal-title":"Arthritis Rheum"},{"issue":"24","key":"1011_CR76","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95(24):e3863.","journal-title":"Medicine (Baltimore)"},{"key":"1011_CR77","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","volume":"197","author":"AC Desbois","year":"2018","unstructured":"Desbois AC, Biard L, Addimanda O, Lambert M, Hachulla E, Launay D, et al. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients. Clin Immunol. 2018;197:54\u20139.","journal-title":"Clin Immunol"},{"issue":"2","key":"1011_CR78","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1756-185X.13778","volume":"23","author":"A Aksoy","year":"2020","unstructured":"Aksoy A, Yazici A, Omma A, Cefle A, Onen F, Tasdemir U, et al. Efficacy of TNF\u03b1 inhibitors for refractory vascular Beh\u00e7et\u2019s disease: a multicenter observational study of 27 patients and a review of the literature. Int J Rheum Dis. 2020;23(2):256\u201361.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"1011_CR79","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1177\/1708538120927701","volume":"28","author":"DY Kehribar","year":"2020","unstructured":"Kehribar DY, Ozgen M. Infliximab treatment in refractory vascular Behcet\u2019s disease: a single-center experience. Vascular. 2020;28(6):829\u201333.","journal-title":"Vascular."},{"issue":"11","key":"1011_CR80","first-page":"2057","volume":"57","author":"Y Ding","year":"2018","unstructured":"Ding Y, Li C, Liu J, Yu X, Wang Y, Shi J, et al. Tocilizumab in the treatment of severe and\/or refractory vasculo-Beh\u00e7et\u2019s disease: a single-centre experience in China. Rheumatology (Oxford). 2018;57(11):2057\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1011_CR81","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","volume":"79","author":"J Liu","year":"2020","unstructured":"Liu J, Hou Y, Sun L, Li C, Li L, Zhao Y, et al. A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2020;79(11):1517\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1011_CR82","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.1097\/MD.0000000000000494","volume":"94","author":"F Alibaz-Oner","year":"2015","unstructured":"Alibaz-Oner F, Karadeniz A, Ylmaz S, Balkarl A, Kimyon G, Yazc A, et al. Beh\u00e7et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94(6):e494.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1011_CR83","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.24393","volume":"61","author":"D Saadoun","year":"2009","unstructured":"Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi HD, Sbai A, et al. Cerebral venous thrombosis in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2009;61(4):518\u201326.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1011_CR84","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","volume":"3","author":"B Zeydan","year":"2016","unstructured":"Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, et al. Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e258.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"23","key":"1011_CR85","doi-asserted-by":"publisher","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","volume":"95","author":"AC Desbois","year":"2016","unstructured":"Desbois AC, Addimanda O, Bertrand A, Deroux A, P\u00e9rard L, Depaz R, et al. Efficacy of anti-TNF\u03b1 in severe and refractory neuro-Behcet disease: an observational study. Medicine (Baltimore). 2016;95(23):e3550.","journal-title":"Medicine (Baltimore)"},{"key":"1011_CR86","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"issue":"12","key":"1011_CR87","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","volume":"57","author":"Y Ozguler","year":"2018","unstructured":"Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, et al. Management of major organ involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford). 2018;57(12):2200\u201312.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1011_CR88","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/art.38351","volume":"66","author":"N Noel","year":"2014","unstructured":"Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D, et al. Long-term outcome of neuro-Beh\u00e7et\u2019s disease. Arthritis Rheum. 2014;66(5):1306\u201314.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1011_CR89","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","volume":"44","author":"O Addimanda","year":"2015","unstructured":"Addimanda O, Pipitone N, Pazzola G, Salvarani C. Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et. Semin Arthritis Rheum. 2015;44(4):472\u20135.","journal-title":"Semin Arthritis Rheum"},{"issue":"3 Suppl 72","key":"1011_CR90","first-page":"S73","volume":"30","author":"P Urbaniak","year":"2012","unstructured":"Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S73\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1011_CR91","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","volume":"114","author":"LS Shapiro","year":"2012","unstructured":"Shapiro LS, Farrell J, Borhani HA. Tocilizumab treatment for neuro-Behcet\u2019s disease, the first report. Clin Neurol Neurosurg. 2012;114(3):297\u20138.","journal-title":"Clin Neurol Neurosurg"},{"issue":"3-4","key":"1011_CR92","first-page":"238","volume":"18","author":"L Cantarini","year":"2016","unstructured":"Cantarini L, Stromillo ML, Vitale A, Lopalco G, Emmi G, Silvestri E, et al. Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet\u2019s disease with different organ involvement: a case series. Isr Med Assoc J. 2016;18(3-4):238\u201342.","journal-title":"Isr Med Assoc J"},{"issue":"12","key":"1011_CR93","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1007\/s00415-015-7897-y","volume":"262","author":"DP Kidd","year":"2015","unstructured":"Kidd DP. Rituximab is effective in severe treatment-resistant neurological Beh\u00e7et\u2019s syndrome. J Neurol. 2015;262(12):2676\u20137.","journal-title":"J Neurol"},{"key":"1011_CR94","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jocn.2016.03.020","volume":"32","author":"J Jade","year":"2016","unstructured":"Jade J, Chung K, Arendse M, Hussain Z, White D. Neuro-Beh\u00e7et\u2019s disease presenting with tumour-like lesions and responding to rituximab. J Clin Neurosci. 2016;32:139\u201341.","journal-title":"J Clin Neurosci"},{"issue":"5","key":"1011_CR95","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1097\/MCG.0b013e3182431d56","volume":"46","author":"YS Jung","year":"2012","unstructured":"Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012;46(5):e38\u201345.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"1011_CR96","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ibd.21757","volume":"18","author":"YS Jung","year":"2012","unstructured":"Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2012;18(4):750\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"16","key":"1011_CR97","doi-asserted-by":"publisher","first-page":"e3348","DOI":"10.1097\/MD.0000000000003348","volume":"95","author":"I Hatemi","year":"2016","unstructured":"Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet's syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95(16):e3348.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1011_CR98","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, et al. Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease. Clin Gastroenterol Hepatol. 2015;13(5):940\u20138.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1011_CR99","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","volume":"62","author":"J Zou","year":"2017","unstructured":"Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ. Long-term outcomes and predictors of sustained response in patients with intestinal Behcet\u2019s disease treated with infliximab. Dig Dis Sci. 2017;62(2):441\u20137.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"1011_CR100","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, et al. Long-term safety and efficacy of adalimumab for intestinal Beh\u00e7et\u2019s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15(3):395\u2013401.","journal-title":"Intest Res"},{"issue":"9","key":"1011_CR101","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of infliximab in intestinal Beh\u00e7et\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19(9):1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1011_CR102","first-page":"116","volume":"35 Suppl 108","author":"J Chen","year":"2017","unstructured":"Chen J, Chen S, He J. A case of refractory intestinal Beh\u00e7et\u2019s disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody. Clin Exp Rheumatol. 2017;35 Suppl 108(6):116\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 84","key":"1011_CR103","first-page":"S175","volume":"32","author":"Y Keskin","year":"2014","unstructured":"Keskin Y, Seyahi E, Poyraz C, Ugurlu S, Ozyazgan Y, Yazici H. Interferon alfa-associated depression in patients with Beh\u00e7et\u2019s syndrome: a prospective controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"1011_CR104","doi-asserted-by":"publisher","first-page":"e0190182","DOI":"10.1371\/journal.pone.0190182","volume":"12","author":"YS Jung","year":"2017","unstructured":"Jung YS, Han M, Kim DY, Cheon JH, Park S. Cancer risk in Korean patients with Beh\u00e7et\u2019s disease: a nationwide population-based study. PLoS One. 2017;12(12):e0190182.","journal-title":"PLoS One"},{"issue":"4","key":"1011_CR105","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s11845-020-02244-0","volume":"189","author":"DC Guven","year":"2020","unstructured":"Guven DC, Bolek EC, Altintop SE, Celikten B, Aktas BY, Kiraz S, et al. Cancer incidence in Beh\u00e7et\u2019s disease. Ir J Med Sci. 2020;189(4):1209\u201314.","journal-title":"Ir J Med Sci"},{"issue":"9","key":"1011_CR106","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","volume":"59","author":"M Gurcan","year":"2020","unstructured":"Gurcan M, Esatoglu SN, Hamuryudan V, Saygin D, Ugurlu S, Seyahi E, et al. Long term follow-up of Beh\u00e7et\u2019s syndrome patients treated with cyclophosphamide. Rheumatology (Oxford). 2020;59(9):2264\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1011_CR107","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11739-018-2000-1","volume":"14","author":"G Mumcu","year":"2019","unstructured":"Mumcu G, Direskeneli H. Triggering agents and microbiome as environmental factors on Beh\u00e7et\u2019s syndrome. Intern Emerg Med. 2019;14(5):653\u201360.","journal-title":"Intern Emerg Med"},{"issue":"4","key":"1011_CR108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/joor.12750","volume":"46","author":"M Yay","year":"2019","unstructured":"Yay M, \u00c7elik Z, Aksoy A, Alibaz-\u00d6ner F, Inan\u00e7 N, Ergun T, et al. Oral health is a mediator for disease severity in patients with Beh\u00e7et\u2019s disease: a multiple mediation analysis study. J Oral Rehabil. 2019;46(4):349\u201354.","journal-title":"J Oral Rehabil"},{"issue":"5","key":"1011_CR109","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1600-0714.2009.00765.x","volume":"38","author":"U Karacayli","year":"2009","unstructured":"Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, et al. The close association between dental and periodontal treatments and oral ulcer course in Behcet\u2019s disease: a prospective clinical study. J Oral Pathol Med. 2009;38(5):410\u20135.","journal-title":"J Oral Pathol Med"},{"issue":"12","key":"1011_CR110","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/ijd.12144","volume":"52","author":"G Mumcu","year":"2013","unstructured":"Mumcu G, Inan\u00e7 N, \u00d6zdemir FT, Tulunay A, Ek\u015fio\u011flu-Demiralp E, Ergun T, et al. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Beh\u00e7et\u2019s disease. Int J Dermatol. 2013;52(12):1561\u20136.","journal-title":"Int J Dermatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01011-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-01011-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01011-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:53:10Z","timestamp":1744138390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-01011-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-01011-z","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Haner Direskeneli participated in the phase 3 study of apremilast by Celgene as a local Principal Investigator. Fatma Alibaz-Oner declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"47"}}